145 related articles for article (PubMed ID: 30996776)
21. Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degrader.
Carmona AV; Jonnalagadda S; Case AM; Maddeboina K; Jonnalagadda SK; Dow LF; Duan L; Penning TM; Trippier PC
Commun Chem; 2024 Apr; 7(1):95. PubMed ID: 38684887
[TBL] [Abstract][Full Text] [Related]
22. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
23. Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Verma K; Zang T; Penning TM; Trippier PC
J Med Chem; 2019 Apr; 62(7):3590-3616. PubMed ID: 30836001
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Sun SQ; Gu X; Gao XS; Li Y; Yu H; Xiong W; Yu H; Wang W; Li Y; Teng Y; Zhou D
Oncotarget; 2016 Jul; 7(30):48050-48058. PubMed ID: 27385003
[TBL] [Abstract][Full Text] [Related]
25. Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Bukum N; Novotna E; Morell A; Hofman J; Wsol V
Chem Biol Interact; 2019 Apr; 302():101-107. PubMed ID: 30703376
[TBL] [Abstract][Full Text] [Related]
26. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
27. Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.
Abbattista MR; Ashoorzadeh A; Guise CP; Mowday AM; Mittra R; Silva S; Hicks KO; Bull MR; Jackson-Patel V; Lin X; Prosser GA; Lambie NK; Dachs GU; Ackerley DF; Smaill JB; Patterson AV
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959631
[TBL] [Abstract][Full Text] [Related]
28. Long-chain fatty acids inhibit human members of the aldo-keto reductase 1C subfamily.
Hara A; Endo S; Matsunaga T; Soda M; Yashiro K; El-Kabbani O
J Biochem; 2017 Nov; 162(5):371-379. PubMed ID: 28992312
[TBL] [Abstract][Full Text] [Related]
29. The role of aldo-keto reductase 1C3 (AKR1C3)-mediated prostaglandin D2 (PGD2) metabolism in keloids.
Mantel A; Newsome A; Thekkudan T; Frazier R; Katdare M
Exp Dermatol; 2016 Jan; 25(1):38-43. PubMed ID: 26308156
[TBL] [Abstract][Full Text] [Related]
30. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes.
Bauman DR; Rudnick SI; Szewczuk LM; Jin Y; Gopishetty S; Penning TM
Mol Pharmacol; 2005 Jan; 67(1):60-8. PubMed ID: 15475569
[TBL] [Abstract][Full Text] [Related]
31. Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.
Tian Y; Zhao L; Wang Y; Zhang H; Xu D; Zhao X; Li Y; Li J
Asian J Androl; 2016; 18(4):607-12. PubMed ID: 26698234
[TBL] [Abstract][Full Text] [Related]
32. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
Novotna R; Wsol V; Xiong G; Maser E
Toxicol Lett; 2008 Sep; 181(1):1-6. PubMed ID: 18616992
[TBL] [Abstract][Full Text] [Related]
33. Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand.
Karunasinghe N; Symes E; Gamage A; Wang A; Murray P; Zhu S; Goudie M; Masters J; Ferguson LR
PLoS One; 2019; 14(5):e0217373. PubMed ID: 31125365
[TBL] [Abstract][Full Text] [Related]
34. Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review.
Karunasinghe N; Masters J; Flanagan JU; Ferguson LR
Curr Cancer Drug Targets; 2017; 17(7):603-616. PubMed ID: 28359237
[TBL] [Abstract][Full Text] [Related]
35. Development of cisplatin resistance in breast cancer MCF7 cells by up-regulating aldo-keto reductase 1C3 expression, glutathione synthesis and proteasomal proteolysis.
Kobayashi M; Yonezawa A; Takasawa H; Nagao Y; Iguchi K; Endo S; Ikari A; Matsunaga T
J Biochem; 2022 Jan; 171(1):97-108. PubMed ID: 34676395
[TBL] [Abstract][Full Text] [Related]
36. Instability of C154Y variant of aldo-keto reductase 1C3.
Endo S; Takada S; Honda RP; Müller K; Weishaupt JH; Andersen PM; Ludolph AC; Kamatari YO; Matsunaga T; Kuwata K; El-Kabbani O; Ikari A
Chem Biol Interact; 2017 Oct; 276():194-202. PubMed ID: 28025170
[TBL] [Abstract][Full Text] [Related]
37. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
Matsunaga T; Hojo A; Yamane Y; Endo S; El-Kabbani O; Hara A
Chem Biol Interact; 2013 Feb; 202(1-3):234-42. PubMed ID: 23165153
[TBL] [Abstract][Full Text] [Related]
38. Investigation of the Potential of Bile Acid Methyl Esters as Inhibitors of Aldo-keto Reductase 1C2: Insight from Molecular Docking, Virtual Screening, Experimental Assays and Molecular Dynamics.
Marinović MA; Petri ET; Grbović LM; Vasiljević BR; Jovanović-Šanta SS; Bekić SS; Ćelić AS
Mol Inform; 2022 Oct; 41(10):e2100256. PubMed ID: 35393780
[TBL] [Abstract][Full Text] [Related]
39. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
40. Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer.
Xie L; Yu J; Guo W; Wei L; Liu Y; Wang X; Song X
Cancer Gene Ther; 2013 Apr; 20(4):260-6. PubMed ID: 23519145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
